Corbion (CRBN) Stock Overview
Provides lactic acid and derivatives, food preservation solutions, functional ingredient systems, and algae-derived nutritional ingredients in the Netherlands, the United States, Asia, rest of Americas, the rest of Europe, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
CRBN Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Materials opportunity
ST
Fair Value from
CA$5.0768.4% undervalued intrinsic discount
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.
Read full narrativeCorbion N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19.22 |
| 52 Week High | €21.64 |
| 52 Week Low | €16.16 |
| Beta | 0.91 |
| 1 Month Change | 2.73% |
| 3 Month Change | -7.33% |
| 1 Year Change | 1.05% |
| 3 Year Change | -33.22% |
| 5 Year Change | -59.31% |
| Change since IPO | -26.56% |
Recent News & Updates
Narrative Update • Apr 22
CRBN: Special Dividend And Execution On Margins Will Support Upside Potential
The updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.
Narrative Update • Apr 08
CRBN: Raised Fair Value And Barclays Downgrade Will Shape Risk Balance
Analysts now set Corbion's fair value at €19.60, up from €18.60. This reflects updated assumptions on growth, margins and P/E multiples, even as some recent research, including a downgrade at Barclays, highlights ongoing risks.
Narrative Update • Mar 24
CRBN: Higher Margins And Special Dividend Will Support Future Re Rating
Analysts have maintained their price target for Corbion at €30.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the main factors supporting the unchanged view. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share, planned for distribution in 2025.Narrative Update • Mar 10
CRBN: Special Dividend And Stronger Margins Will Support A More Optimistic Outlook
Analysts have trimmed their price target on Corbion from €24.60 to about €24.17, reflecting updated views on its projected revenue growth, profit margins, and future P/E assumptions. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share for 2025, which may influence your expected cash returns from holding the stock (Key Developments).Recent updates
Narrative Update • Apr 22
CRBN: Special Dividend And Execution On Margins Will Support Upside Potential
The updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.Narrative Update • Apr 08
CRBN: Raised Fair Value And Barclays Downgrade Will Shape Risk Balance
Analysts now set Corbion's fair value at €19.60, up from €18.60. This reflects updated assumptions on growth, margins and P/E multiples, even as some recent research, including a downgrade at Barclays, highlights ongoing risks.Narrative Update • Mar 24
CRBN: Higher Margins And Special Dividend Will Support Future Re Rating
Analysts have maintained their price target for Corbion at €30.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the main factors supporting the unchanged view. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share, planned for distribution in 2025.Narrative Update • Mar 10
CRBN: Special Dividend And Stronger Margins Will Support A More Optimistic Outlook
Analysts have trimmed their price target on Corbion from €24.60 to about €24.17, reflecting updated views on its projected revenue growth, profit margins, and future P/E assumptions. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share for 2025, which may influence your expected cash returns from holding the stock (Key Developments).Narrative Update • Feb 24
CRBN: Higher Future P/E Assumptions Will Support A More Optimistic Outlook
Analysts have raised their price target on Corbion from about €22.73 to €24.60, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E levels. Valuation Changes Fair Value: Updated estimate increased from about €22.73 to €24.60 per share.Narrative Update • Feb 09
CRBN: Buyback And Higher Discount Rate Will Pressure Overvalued Shares
Analysts have kept their price target on Corbion steady at €18.60, citing only small adjustments to assumptions around the discount rate, revenue trends, profit margins and future P/E as the basis for this unchanged view. What's in the News Corbion completed a share buyback program, repurchasing 577,615 shares for €10 million, equal to 0.99% of the company.Narrative Update • Jan 26
CRBN: Higher Future P/E And Execution Risks Will Shape EUR 18 Outlook
Narrative Update on Corbion Analysts have raised their fair value estimate for Corbion to €18.60 from €18.00. This reflects updated views on discount rates, long term revenue trends, profit margins, and a higher future P/E assumption, alongside recent Street research where a key price target moved to €18 from €16.50.Analysis Article • Jan 14
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it saw a double-digit share price rise of over 10...Narrative Update • Jan 11
CRBN: Future P/E Reset And Margin Assumptions Will Shape EUR 18 Outlook
Analysts have raised their price target for Corbion to €18 from €16.50, citing updated assumptions on revenue trends, margins and future P/E as the main factors behind the change. Analyst Commentary The revised €18 price target still comes with a Hold stance, which signals a measured view on Corbion.Narrative Update • Dec 26
CRBN: Higher EUR 18 Outlook Will Test Margin Delivery Amid Muted Demand
Analysts have raised their fair value estimate for Corbion to EUR 18 from EUR 14, reflecting increased confidence in the company’s profit margin outlook and a willingness to apply a higher future earnings multiple despite more muted revenue growth expectations. Analyst Commentary Bearish analysts acknowledge the higher fair value estimate but continue to highlight a cautious stance on Corbion’s near term prospects, emphasizing that the improved target largely reflects valuation mechanics rather than a fundamental re-rating of the growth outlook.Narrative Update • Dec 12
CRBN: Margin Improvements And Buybacks Will Support A Future Re-Rating
Analysts have lowered their fair value price target on Corbion to EUR 30.00 from EUR 31.90, citing tempered expectations for long term revenue growth and profit margins, even as some recent Street research has modestly raised nearer term share price targets. Analyst Commentary Bullish analysts highlight that the recent upward revision in near term price targets, even from a relatively low base, reflects growing confidence that Corbion can stabilize its earnings profile and execute on margin improvement initiatives.Analysis Article • Nov 14
Corbion N.V. (AMS:CRBN) Shares Could Be 35% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €28.50 Current share price of...Analysis Article • Jun 23
Corbion N.V.'s (AMS:CRBN) Intrinsic Value Is Potentially 65% Above Its Share Price
Key Insights The projected fair value for Corbion is €30.72 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • May 07
Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely
Key Insights Corbion's Annual General Meeting to take place on 14th of May Salary of €725.0k is part of CEO Olivier...Analysis Article • Apr 10
At €17.39, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw significant share price movement during recent...Analysis Article • Mar 26
Corbion's (AMS:CRBN) Earnings May Just Be The Starting Point
Corbion N.V.'s ( AMS:CRBN ) earnings announcement last week was disappointing for investors, despite the decent profit...
New Narrative • Mar 02
Expanding Into Natural Antioxidants And Efficiency Improvements Will Drive Future Success
Strategic initiatives and operational optimizations are expected to significantly enhance EBITDA margins and net margins.Analysis Article • Feb 28
Here's What To Make Of Corbion's (AMS:CRBN) Decelerating Rates Of Return
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysis Article • Dec 18
Risks To Shareholder Returns Are Elevated At These Prices For Corbion N.V. (AMS:CRBN)
It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 15.8x right now seems...Analysis Article • Nov 18
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it received a lot of attention from a substantial price...Analysis Article • Oct 31
An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €31.60 Corbion's €23.28 share...Analysis Article • Sep 26
Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jul 18
The Price Is Right For Corbion N.V. (AMS:CRBN)
It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 16.1x right now seems...Analysis Article • Jun 20
Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €25.18 Corbion is estimated to...Analysis Article • May 08
Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely
Key Insights Corbion will host its Annual General Meeting on 15th of May Salary of €713.0k is part of CEO Olivier...Analysis Article • Apr 17
Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jan 20
Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is Lacking
There wouldn't be many who think Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 14.3x is worth a...Analysis Article • Dec 18
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...Analysis Article • Nov 04
Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €15.91 Corbion's €17.30 share...Analysis Article • Sep 13
Corbion (AMS:CRBN) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Aug 04
Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Analysis Article • Jul 14
When Should You Buy Corbion N.V. (AMS:CRBN)?
While Corbion N.V. ( AMS:CRBN ) might not be the most widely known stock at the moment, it received a lot of attention...Analysis Article • Jun 04
Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value Estimate
Key Insights The projected fair value for Corbion is €21.22 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Apr 21
Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 10
Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56
Corbion N.V. ( AMS:CRBN ) has announced that it will pay a dividend of €0.56 per share on the 30th of May. The dividend...Analysis Article • Feb 22
Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?
Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it received a lot of attention from a substantial...Analysis Article • Jan 26
Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Analysis Article • Dec 20
Is Corbion (AMS:CRBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Nov 24
Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)
Today we will run through one way of estimating the intrinsic value of Corbion N.V. ( AMS:CRBN ) by taking the expected...Analysis Article • Nov 09
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...Analysis Article • Oct 08
Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital Effectively
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Sep 19
Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Aug 23
A Look At The Intrinsic Value Of Corbion N.V. (AMS:CRBN)
Today we will run through one way of estimating the intrinsic value of Corbion N.V. ( AMS:CRBN ) by taking the expected...Shareholder Returns
| CRBN | NL Chemicals | NL Market | |
|---|---|---|---|
| 7D | 2.2% | 6.0% | 5.4% |
| 1Y | 1.1% | -22.5% | 32.9% |
Return vs Industry: CRBN exceeded the Dutch Chemicals industry which returned -27.4% over the past year.
Return vs Market: CRBN underperformed the Dutch Market which returned 28.3% over the past year.
Price Volatility
| CRBN volatility | |
|---|---|
| CRBN Average Weekly Movement | 3.8% |
| Chemicals Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in NL Market | 8.1% |
| 10% least volatile stocks in NL Market | 2.9% |
Stable Share Price: CRBN has not had significant price volatility in the past 3 months compared to the Dutch market.
Volatility Over Time: CRBN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1903 | 2,410 | Olivier Rigaud | www.corbion.com |
Corbion N.V. provides lactic acid and derivatives, food preservation solutions, functional ingredient systems, and algae-derived nutritional ingredients in the Netherlands, the United States, Asia, rest of Americas, the rest of Europe, the Middle East, and Africa. It operates in two segments, Functional Ingredients & Solutions, and Health & Nutrition. The company offers antioxidants, fermentation and preservation ingredients, flavors, fortification, functional blends, and lactic acid lactates and derivatives; AlgaPrime DHA, an omega-3 sourcing product; AlgaVia which develops foods and beverages with reduced saturated fat content; CALFEED, a dry lactic acid source to boost feed intake for swine or poultry; LAFEED that helps feed intake and digestive health; LAFEED Powder that acts as a preservative and acidulate; PURAC DW, provides an acidifier, preservative, and antimicrobial in teat-dip applications for animals; PURAC Pet food; PURASOLV; and PURASOLV EL.
Corbion N.V. Fundamentals Summary
| CRBN fundamental statistics | |
|---|---|
| Market cap | €1.11b |
| Earnings (TTM) | €74.80m |
| Revenue (TTM) | €1.27b |
14.8x
P/E Ratio0.9x
P/S RatioIs CRBN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRBN income statement (TTM) | |
|---|---|
| Revenue | €1.27b |
| Cost of Revenue | €932.70m |
| Gross Profit | €334.70m |
| Other Expenses | €259.90m |
| Earnings | €74.80m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 31, 2026
| Earnings per share (EPS) | 1.30 |
| Gross Margin | 26.41% |
| Net Profit Margin | 5.90% |
| Debt/Equity Ratio | 53.8% |
How did CRBN perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield50%
Payout RatioDoes CRBN pay a reliable dividends?
See CRBN dividend history and benchmarks| Corbion dividend dates | |
|---|---|
| Ex Dividend Date | May 15 2026 |
| Dividend Pay Date | May 22 2026 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 15 days |
Does CRBN pay a reliable dividends?
See CRBN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 03:22 |
| End of Day Share Price | 2026/05/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Corbion N.V. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Setu Sharda | Barclays |
| Sebastian Bray | Berenberg |
| Fintan Ryan | Berenberg |